Conduit Pharmaceuticals (CDT) announced that the Company received formal notice from The Nasdaq Stock Market that the Company has regained compliance with Nasdaq’s minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq’s stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1). The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Inc trading halted, news pending
- Upcoming Stock Splits This Week (May 19 to May 23) – Stay Invested
- Conduit Pharmaceuticals Announces Reverse Stock Split
- Conduit Pharmaceuticals announces 1-for-15 reverse stock split
- Conduit Pharmaceuticals receives patent approval for AZD1656